Laboratorio Reig Jofre (BME:RJF) Second Quarter 2024 Results
Key Financial Results
- Revenue: €86.3m (up 8.6% from 2Q 2023).
- Net income: €2.27m (up 22% from 2Q 2023).
- Profit margin: 2.6% (up from 2.3% in 2Q 2023). The increase in margin was driven by higher revenue.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Laboratorio Reig Jofre Earnings Insights
Looking ahead, revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Europe.
Performance of the market in Spain.
The company's shares are down 1.1% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for Laboratorio Reig Jofre you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About BME:RJF
Laboratorio Reig Jofre
A pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics.
Excellent balance sheet with reasonable growth potential.
